semaglutide and heart attack The weight-loss drug Wegovy lowered risk in a large trial Semaglutide cardiovascular outcomes align more

There's a scientific explanation

This is a regulatory limitation, not a choice we make

Semaglutide tends to be the better fit when: the goal is a 10 to 15 percent weight reduction, the patient has documented cardiovascular disease or is at high cardiovascular risk and wants the medication with the most outcomes data, cost or access constraints favor it, or the patient has tolerated single-pathway GLP-1s well in the past

We know that people are buying this from unregulated sources, and sometimes what you think youre buying isnt what youre actually getting. Ensuring anyone taking it is also making healthy lifestyle changes, such as incorporating better nutrition and fitness practices, is also key